Evaxion Biotech A/S (EVAX) has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. to evaluate the combination of Evaxion's cancer immunotherapy EVX-01 with MSD's KEYTRUDA in a new phase 2b study. Evaxion will be responsible for the conduct of the study.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Evaxion Biotech A/S (EVAX) has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. to evaluate the combination of Evaxion's cancer immunotherapy EVX-01 with MSD's KEYTRUDA in a new phase 2b study. Evaxion will be responsible for the conduct of the study.

RTTNews | Oct 25, 2021 05:52AM EDT

05:51 Monday, October 25, 2021 (RTTNews.com) - Evaxion Biotech A/S (EVAX) has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. to evaluate the combination of Evaxion's cancer immunotherapy EVX-01 with MSD's KEYTRUDA in a new phase 2b study. Evaxion will be responsible for the conduct of the study.

Evaxion noted that the ongoing phase 1/2a trial is investigating EVX-01 for the treatment of patients with melanoma.

Evaxion Biotech said the collaboration will also reduce the cost of conducting the phase 2b trial on EVX-01.

Read the original article on RTTNews ( https://www.rttnews.com/3235031/evaxion-announces-collaboration-with-merck-co-to-evaluate-evx-01-with-keytruda.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved